Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7324340 | 0.90 | ALDH1A1 (0.61) | TSHRALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL7694497 | 0.85 | ALDH1A1 (0.57) | TSHRALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL6959131 | 0.85 | TDP1 (0.48) | TSHRALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL913926 | 0.84 | PPARG (0.47) | TSHRALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL5207507 | 0.79 | L3MBTL1 (0.59) | TSHRALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL10898655 | 0.79 | KMT2A (0.48) | ALDH1A1L3MBTL1LMNACES2CES1 | |
| SCHEMBL8429828 | 0.79 | LMNA (0.38) | ALDH1A1L3MBTL1LMNAKDM4E | |
| SCHEMBL10469926 | 0.79 | ALDH1A1 (0.53) | TSHRALDH1A1MAPK1TDP1L3MBTL1 | |
| 1,3-Dimethoxybenzene SCHEMBL27728370 | 0.79 | ALDH1A1 (0.62) | TSHRALDH1A1MAPK1TDP1L3MBTL1 | |
| SCHEMBL6839231 | 0.78 | KMT2A (0.50) | ALDH1A1TDP1MTNR1BMTNR1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| EP-2125782-B1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| EP-2125782-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101905-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | CYP2D6, CYP2B6, CYP2C9 | TSHR 750/4885ALDH1A1 123/4885MAPK1 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.